Insulin Delivery Device
Dec 01, 2022
AnchorDx’s UriFind Bladder Cancer Assay in the US; UroMems Initiates Smart Implant to Treat Stress Urinary Incontinence; FDA 510(k) Clearance to NeuroLogica’s BodyTom 64; CE-IVD Mark Approval to SeekInCure’s Recurrence Monitoring Kit Gets; Ypsomed and CamDiab’s Automated Insulin Dosing System; Boston Scientific to Acquire Apollo Endosurgery
AnchorDx Clinical Trial Enrols First Patient for its UriFind® Bladder Cancer Assay in the US On November 23, 2022, AnchorDx, announced the first patient enrollment for its clinical trials of the UriFind® bladder cancer assay in the United States. The UriFind® bladder cancer assay clinical trial in the U...
Read More...
Jul 19, 2021
Cost-effectiveness, Advanced Technology, Rising Demand Pushes the Insulin Delivery Devices Market
Insulin is a hormone secreted by the beta cells of the islets of langerhans in the pancreas. The hormone is responsible for the maintenance of normal blood glucose levels by facilitating cellular glucose uptake and regulating carbohydrate, protein, and lipid metabolism. Inappropriate functioning of insulin due to d...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
